Fondaparinux treatment in heparin induced thrombocytopenia: Case report Heparinin i̇ndüklediǧi trombositopenide fondaparinux tedavisi: Olgu sunumu

Akagün T., SÖNMEZ M., YILMAZ M., Akdoǧan E., Durmuş A., Ovali E., ...Daha Fazla

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.16, sa.3, ss.141-144, 2006 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 3
  • Basım Tarihi: 2006
  • Dergi Adı: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.141-144
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Heparin induced thrombocytopenia (HIT) is a complication of heparin therapy, that is associated with thrombocytopenia, arterial and venous thromboembolism. HIT usually develops 5 and 14 days after commencement of heparin therapy. HIT is a situation that has high mortality if it is not treated. When HIT is suspected, all forms of heparin should be discontinued and treatment with a direct thrombin inhibitor should be initiated. Fondaparinux is a synthetic pentasaccharide anticoagulant drug which is used for the treatment of HIT. Our case represents thrombocytopenia / thrombosis as a complication of heparin therapy. We tried to make an overview of new treatment choices.